IL17A and neoplasm: In contrast, M2 TAMs suppress the immune response via the secretion of TGF‐β, IL‐10, and arginase 1 and stimulate tumor growth through the secretion of IL‐17, IL‐23, and pro‐angiogenic factors [33].